Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 87 | 10 | 77 |
| Samples | 84 | 10 | 74 |
| Peptides | 69 | 9 | 63 |
Function
MARCH5 · E3 ubiquitin-protein ligase MARCHF5
Mitochondrial E3 ubiquitin-protein ligase that plays a crucial role in the control of mitochondrial morphology by acting as a positive regulator of mitochondrial fission and as an important regulator of immune response (PubMed:16874301, PubMed:17606867, PubMed:26246171, PubMed:31881323). Plays a crucial role in maintaining mitochondrial homeostasis by regulating the dynamics of mitochondria through the ubiquitination of key proteins involved in fission and fusion such as FIS1, DNM1L and MFN1 (PubMed:16874301, PubMed:17606867). Acts as a critical determinant of mitotic apoptosis through both MCL1-dependent and -independent pathways (By similarity). Turns off persistent immune signaling by degrading oligomeric complexes of retinoic acid-inducible gene I/DDX58 and mitochondrial antiviral-signaling protein/MAVS formed upon RNA virus infection (PubMed:26246171, PubMed:31881323, PubMed:40071916). Promotes STING-mediated type-I interferon production via 'Lys-63'-linked ubiquitination of STING1 thereby preserving its activity and preventing the formation of inactive STING1 polymers (PubMed:37916870). Plays also an essential role in the formation of PEX3-containing vesicles in the de novo biogenesis of peroxisomes from mitochondria (PubMed:39423820, PubMed:39423819). Acts as a regulator of NLRP3 inflammasome activation on the mitochondria by mediating the 'Lys-27'-linked polyubiquitination of NLRP3, positively regulating the NLRP3-NEK7 complex formation and NLRP3 oligomerization (PubMed:37575012)
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000358935 | Q9NX47 | 87 | 69 |
Gene Properties
Recurrent Mutations
All 69 amino-acid changes on canonical ENST00000358935 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MARCH5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MARCH5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 8/612 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Colorectal Carcinoma | 4/143 3% | 9/3239 0% |
| Other Solid Cancers | 0/94 0% | 5/1515 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 4/1390 0% |
| Melanoma | 1/210 0% | 4/1899 0% |
| Glioma | 0/52 0% | 5/2127 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 2/810 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| Gastric Carcinoma | 0/74 0% | 4/1809 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Breast Carcinoma | 1/144 1% | 4/3264 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Neuroendocrine Tumour | 0/154 0% | 1/577 0% |
| Other Sarcomas | 1/69 1% | 0/699 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 3/2550 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Bladder Carcinoma | 0/58 0% | 1/956 0% |
| Head and Neck Carcinoma | 0/85 0% | 1/1574 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
Mutation Distribution
Where MARCH5 is mutated · all tissues, split by cell line vs tissue
How many mutations in MARCH5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 87 mutations in MARCH5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|